Amphastar Pharma

Forecast & Rating7 analysts currently cover Amphastar Pharma, with about 0.0% giving a positive rating — meaning they expect the stock to rise. The average price target is $22.00, about 17.5% upside from the current price of $18.72. Price targets span a fair range, indicating some disagreement among institutions. Historically, about 63.9% of past price targets were eventually met, which adds credibility. For you, this means most institutions are cautious on Amphastar Pharma's outlook. Data as of Jul 23, 2026; for reference only and not investment advice.